Canada-based Theratechnologies has unveiled positive Phase III results evaluating the long-term safety profile of tesamorelin (TH9507), in patients with HIV-associated lipodystrophy. The long-term results are consistent with the safety profile observed in the first 26 weeks of treatment and show that tesamorelin is well tolerated.
"Our objective was to demonstrate long-term safety, and we have clearly achieved this. In addition, we continue to differentiate tesamorelin from other compounds being evaluated in HIV-associated lipodystrophy as having a favorable risk/benefit profile for patients," commented Mr. Yves Rosconi, President and CEO of Theratechnologies.
- check out Theratechnologies' release for more